Loading...
•
Dec 31, 2020
Alnylam Q4 2020 Earnings Report
Alnylam reported strong Q4 2020 results, marked by significant revenue growth and regulatory approvals.
Key Takeaways
Alnylam Pharmaceuticals reported a strong fourth quarter and full year 2020, with global net product revenues reaching $113 million for the quarter and $362 million for the year. The company achieved regulatory approvals for OXLUMO in the EU and U.S., and Leqvio in the EU. Alnylam launched its 'P5x25' strategy and reported positive results from the HELIOS-A Phase 3 study of Vutrisiran.
Global net product revenues reached $113 million in Q4 2020 and $362 million for the full year.
Regulatory approvals achieved for OXLUMO in the EU and U.S., and Leqvio by Novartis in the EU.
Launched 'Alnylam P5x25' strategy for planned transition to a top five biotech.
Reported positive topline results from HELIOS-A Phase 3 study of Vutrisiran.
Alnylam
Alnylam
Alnylam Revenue by Segment
Revenue by Segment
ONPATTRO Revenue
CapyFin.comGIVLAARI Revenue
CapyFin.comOXLUMO Revenue
CapyFin.com Forward Guidance
Alnylam anticipates continued growth in 2021, driven by increased disease awareness, patient identification, and global expansion. The company expects to achieve combined net product revenues between $610 million and $660 million for the full year 2021.
Positive Outlook
- Combined net product revenues for 2021 are projected to be between $610 million and $660 million.
- Continued growth is expected from ONPATTRO and GIVLAARI.
- Global commercial capabilities will be leveraged for the launch of OXLUMO.
- Disciplined investment in operations will continue.
- The company aims to transition toward a self-sustainable financial profile.
Challenges Ahead
- The direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic
- Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates
- Actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement
- Delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products
- Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing
Revenue & Expenses
Visualization of income flow from segment revenue to net income